PBA
ZNTL icon

Paradigm Biocapital Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-944,917
Closed -$14.9M – 42
2024
Q1 		$14.9M Buy
944,917
+544,917
+136% +$7.5M 0.52% 30
2023
Q4 		$6.06M Buy
+400,000
New +$5.84M 0.28% 28
2022
Q2 		– Sell
-287,577
Closed -$13.3M – 28
2022
Q1 		$13.3M Sell
287,577
-12,857
-4% -$694K 3.51% 13
2021
Q4 		$25.3M Buy
+300,434
New +$23.2M 7.21% 3

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Paradigm Biocapital Advisors's ZNTL Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 944,917 shares — an estimated $14.9M sold.

Paradigm Biocapital Advisors first reported a position in ZNTL in Q4 2021 and held it in 4 quarters. The position peaked at $25.3M in Q4 2021. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 944,917 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $14.9M.
  • Paradigm Biocapital Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Zentalis Pharmaceuticals position peaked at $25.3M in Q4 2021.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.